Table 4.

Univariate and multivariate analyses for the relationship between the response to the gemcitabine-containing regimens and patients’ background or toxicity by gemcitabine-containing regimens

	n (%)	Univariete analysis	Multivariate analysis
		P-value	OR (95% CI)	P-value
Sex
Male	102 (60.3)	0.5621	1.39 (0.632–3.058)	0.4129
Female	67 (39.7)
Age
≧65	90 (53.3)	0.4144	1.733 (0.765–3.926)	0.1877
<65	79 (46.7)
Antibiotics
Untreated	93 (55.0)	0.0305	2.444 (1.083–5.519)	0.0314
Treated	76 (45.0)
Severe (grade 3 or 4) neutropenia
Negative	110 (65.1)	0.6975	0.696 (0.293–1.651)	0.4103
Positive	59 (34.9)
Operaion history
Negative	123 (72.8)	0.1148	0.364 (0.129–1.033)	0.0577
Positive	46 (27.2)
Tumor stage
III	15 (8.9)	0.4360	2.321 (0.473–11.392)	0.2995
IV	154 (91.1)
Cancer type
Pancreatic cancer	105 (62.1)	0.7799	0.919 (0.383–2.205)	0.8500
Other cancers	64 (37.9)
Type of GEM-containing regimen
GEM alone	82 (48.5)	0.0700	1.997 (0.842–4.738)	0.1165
Combination of GEM and other anticancer drug	87 (51.5)

Note: P-values were analyzed using Pearson’s chi-square test.

Abbreviation: GEM, gemcitabine.